Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
- Authors: Puig L.1, Bakulev A.L.2, Kokhan M.M.3, Samtsov A.V.4, Khairutdinov V.R.4, Morozova M.A.5, Zolkin N.A.5, Kuryshev I.V.5, Petrov A.N.5, Artemeva A.V.5, Zinkina-Orikhan A.V.5
-
Affiliations:
- Hospital de Sant Pau
- Saratov State Medical University
- Ural Research Institute of Dermatovenereology and Immunopathology
- S.M. Kirov Military Medical Academy
- JSC BIOCAD
- Issue: Vol 97, No 4 (2021)
- Pages: 80-91
- Section: ORIGINAL STUDIES
- URL: https://journals.rcsi.science/0042-4609/article/view/117597
- DOI: https://doi.org/10.25208/vdv1251
- ID: 117597
Cite item
Full Text
Abstract
Background. Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate to severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 trial.
Aim. To evaluate the efficacy and safety of two NTK regimens vs. placebo in moderate to severe plaque psoriasis.
Methods. PLANETA is the ongoing randomized double-blind placebo-controlled clinical trial. 213 patients with moderate to severe plaque psoriasis were randomly assigned to receive NTK 120 mg once every 2 weeks (NTK Q2W), NTK 120 mg once every 4 weeks (NTK Q4W) or placebo. During the first 3 weeks, patients received subcutaneous injections of NTK or placebo (according to the allocation) once a week. Patients in the NTK Q2W group then received NTK at weeks 4, 6, 8, and 10. Subjects in the NTK Q4W group received NTK at weeks 6 and 10 and placebo at weeks 4 and 8. Patients in the placebo group received placebo injections at weeks 4, 6, 8, and 10. Treatment was unblinded at week 12. During the open-label phase, patients in both NTK groups continued to receive NTK Q4W. The primary efficacy endpoint was the proportion of patients in each group who achieved a 75% or greater reduction from baseline in psoriasis area and severity index (PASI 75) at week 12.
Results. A total of 77.7%, 83.3%, and 0% of patients had a PASI 75 response at week 12 in the NTK Q2W, NTK Q4W, and placebo groups, respectively (P < 0.0001, Fisher’s exact test, ITT). The effect was maintained throughout the 1-year treatment. NTK showed a good safety profile and low immunogenicity.
Conclusion. Treatment with NTK results in high rates of sustained clinical response in patients with moderate to severe plaque psoriasis. The study is ongoing; thus, long-term use efficacy and safety data are forthcoming.
Full Text
##article.viewOnOriginalSite##About the authors
Luis Puig
Hospital de Sant Pau
Email: LPuig@santpau.cat
ORCID iD: 0000-0001-6083-0952
MD (Hon), PhD
Spain, Sant Quinti, 89, BarcelonaAndrey L. Bakulev
Saratov State Medical University
Author for correspondence.
Email: al_ba05@mail.ru
ORCID iD: 0000-0002-1450-4942
MD, Dr. Sci. (Med.), Professor
Russian Federation, Bolshaya Kazachia str., 112, Saratov
Muza M. Kokhan
Ural Research Institute of Dermatovenereology and Immunopathology
Email: mkokhan@yandex.ru
ORCID iD: 0000-0001-6353-6644
MD, Dr. Sci. (Med.), Professor
Russian Federation, Shcherbakova str., 8, YekaterinburgAlexey V. Samtsov
S.M. Kirov Military Medical Academy
Email: avsamtsov@mail.ru
ORCID iD: 0000-0002-9458-0872
MD, Dr. Sci. (Med.), Professor
Russian Federation, Akаdemika Lebedeva str. 6, Saint PetersburgVladislav R. Khairutdinov
S.M. Kirov Military Medical Academy
Email: haric03@list.ru
ORCID iD: 0000-0002-0387-5481
Dr. Sci. (Med.), assistant professor
Russian Federation, Akаdemika Lebedeva str. 6, Saint PetersburgMaria A. Morozova
JSC BIOCAD
Email: morozovama@biocad.ru
ORCID iD: 0000-0001-7755-7526
SPIN-code: 5651-1479
MD, Cand. Sci. (Med.)
Russian Federation, Svyazi st., 34-A, Saint Petersburg, StrelnaNikita A. Zolkin
JSC BIOCAD
Email: zolkin@biocad.ru
ORCID iD: 0000-0002-7938-710X
Russian Federation, Svyazi st., 34-A, Saint Petersburg, Strelna
Ivan V. Kuryshev
JSC BIOCAD
Email: kuryshev@biocad.ru
ORCID iD: 0000-0001-8095-8734
Russian Federation, Svyazi st., 34-A, Saint Petersburg, Strelna
Alexey N. Petrov
JSC BIOCAD
Email: petrovan@biocad.ru
Russian Federation, Svyazi st., 34-A, Saint Petersburg, Strelna
Antonina V. Artemeva
JSC BIOCAD
Email: artemevaav@biocad.ru
ORCID iD: 0000-0002-5306-3377
Russian Federation, Svyazi st., 34-A, Saint Petersburg, Strelna
Arina V. Zinkina-Orikhan
JSC BIOCAD
Email: zinkina@biocad.ru
ORCID iD: 0000-0002-8499-2232
Russian Federation, Svyazi st., 34-A, Saint Petersburg, Strelna
References
- Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2012;122(11):487–511. doi: 10.1042/CS20110496
- Erdes S, Nasonov E, Kunder E, Pristrom A, Soroka N, Shesternya P, et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. 2020;38(1):27–34.
- Бакулев А.Л., Самцов А.В., Кубанов А.А., Хайрутдинов В.Р., Кохан М.М., Артемьева А.В., и др. Долгосрочная эффективность и безопасность препарата нетакимаб у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Результаты открытого продленного клинического исследования II фазы BCD-085-2-ext. Вестник дерматологии и венерологии. 2019;95(3):54–64. [Bakulev AL, Samтsоv AV, Kubanov AA, Hajrutdinov VR, Kohan MM, Artem'eva AV, et al. Dolgosrochnaja jeffektivnost' i bezopasnost' preparata netakimab u pacientov so srednetjazhelym i tjazhelym vul'garnym psoriazom. Rezul'taty otkrytogo prodlennogo klinicheskogo issledovanija II fazy BCD-085-2-ext. Vestnik dermatologii i venerologii. 2019;95(3):54–64 (In Russ.)]. doi: 10.25208/0042-4609-2019-95-3-54-64
- Common Terminology Criteria for Adverse Events (CTCAE). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
- Farahnik B, Beroukhim K, Zhu TH, Abrouk M, Nakamura M, Singh R, et al. Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatol Ther (Heidelb). 2016;6(1):25–37. doi: 10.1007/s13555-016-0102-0
- European medical Agency. Assessment Report EMA/CHMP/389874/2014. https://www.ema.europa.eu/en/documents/assessment-report/cosentyx-epar-public
- Gordon KB, Colombel JF, Hardin DS. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016;375(21):2102. doi: 10.1056/NEJMc1610828
- Spuls PI, Witkamp L, Bossuyt PM, Bos JD. The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol. 2004;140(3):338–44; discussion 44. doi: 10.1001/archderm.140.3.338
Supplementary files
